By Daniel Akselrod · Licensed Attorney · July 2026

Intake Forms for Rheumatology Practices: Joint Symptoms, Autoimmune Screening, and Medication History

A patient walks into a rheumatology office with pain in both hands, stiffness that lasts an hour every morning, and a referral note that reads "joint pain — rule out RA." The rheumatologist has roughly fifteen minutes to determine whether this is rheumatoid arthritis, osteoarthritis, psoriatic arthritis, lupus with joint involvement, gout, or one of another dozen conditions that present with polyarticular pain. The intake form that patient filled out in the waiting room is the single most important tool for making that clinical decision efficient, because every minute the rheumatologist spends asking baseline questions that should have been captured on paper is a minute lost from the physical examination and the diagnostic reasoning that actually drives the treatment plan.

Rheumatology is a specialty where the intake form does more than administrative work. It performs a preliminary clinical sort. The right questions, asked in the right order, allow the physician to walk into the exam room already forming a differential diagnosis. The wrong form — a generic musculoskeletal template borrowed from orthopedics, or a primary care intake with a few joint questions appended — forces the rheumatologist to start from scratch, extending visit times and delaying the moment when the real clinical conversation begins.

Joint symptom assessment: the foundation of the rheumatology intake

The joint symptom section of a rheumatology intake form is not a simple pain questionnaire. It is a structured diagnostic instrument that, when designed correctly, begins differentiating inflammatory from mechanical disease before the patient enters the exam room. The form should capture which joints are affected, whether the pattern is symmetric or asymmetric, the duration and timing of stiffness, whether swelling is present, and whether the pain pattern suggests inflammation or degeneration. Each of these data points narrows the differential in clinically meaningful ways.

A homunculus-style joint diagram — front and back views of the body with joints marked for the patient to circle or shade — captures distribution faster than any checkbox list. But the diagram alone is insufficient. The form needs to ask about symmetry explicitly, because a patient with symmetric involvement of the metacarpophalangeal joints is telling a fundamentally different story than a patient with unilateral knee swelling. Symmetric small-joint polyarthritis points toward rheumatoid arthritis. Asymmetric oligoarthritis involving large joints and the DIP joints suggests psoriatic arthritis or reactive arthritis. First MTP involvement with acute onset screams gout. The distribution pattern is diagnostic data, and the form must capture it with enough granularity to be useful.

Morning stiffness duration is one of the most clinically valuable fields on the entire form, and it is frequently either missing or poorly designed. The form should not ask whether the patient has morning stiffness — nearly every patient with joint complaints will say yes. It should ask how long the stiffness lasts before improving. Inflammatory arthritis typically produces morning stiffness lasting more than thirty minutes, often an hour or more. Osteoarthritis produces stiffness that resolves within fifteen to twenty minutes, sometimes described more as "gelling" after inactivity than true prolonged morning stiffness. This single data point — duration in minutes — is one of the strongest intake-level discriminators between inflammatory and degenerative disease. The form should present it as a fill-in field with a prompt like "How many minutes does your morning stiffness last before it begins to improve?" rather than a vague yes/no checkbox.

Swelling is another field that demands precision. Patients use the word "swelling" to describe objective joint effusion, subjective feelings of puffiness, bony enlargement from osteophytes, and soft tissue edema around tendons. The form should distinguish between joints that appear visibly swollen, joints that feel swollen without visible change, and joints with bony bumps or nodules. Visible, warm, fluctuant swelling suggests active synovitis. Hard, bony enlargement at the DIP or PIP joints suggests Heberden or Bouchard nodes — hallmarks of osteoarthritis. The treatment implications could not be more different, and the intake form is the first opportunity to make this distinction.

Systemic autoimmune screening: looking beyond the joints

Rheumatic diseases are systemic. A patient presenting with joint pain may also have lupus with renal involvement, systemic sclerosis with pulmonary fibrosis, or Sjogren syndrome that has been misdiagnosed as allergies for a decade. The intake form must screen for extra-articular manifestations because the patient will not volunteer them unless specifically asked — they do not connect the rash on their face to the pain in their knees.

The autoimmune screening section should cover skin findings first. A malar rash — the butterfly-shaped erythema across the cheeks and bridge of the nose — is the classic lupus sign, but patients frequently dismiss it as sun sensitivity or rosacea. Photosensitivity itself is diagnostically significant, as it appears in lupus, dermatomyositis, and drug-induced photosensitivity from hydroxychloroquine. The form should ask about rashes on the face, scalp, or chest, skin thickening on the fingers or hands, nail changes including pitting or onycholysis, and any skin lesions that worsen with sun exposure. Each of these points toward a different rheumatic condition, and collectively they build a systemic picture that pure joint questioning misses entirely.

Oral ulcers, dry eyes, and dry mouth are three symptoms that patients rarely bring up in a joint-pain visit but that carry significant diagnostic weight. Recurrent oral ulcers appear in lupus and Behcet disease. Dry eyes and dry mouth — sicca symptoms — are the hallmark of Sjogren syndrome but also appear as secondary features of rheumatoid arthritis and lupus. Raynaud phenomenon, where the fingers turn white then blue then red in response to cold or stress, is present in systemic sclerosis, mixed connective tissue disease, and lupus. Hair loss, particularly diffuse non-scarring alopecia, is a feature of active lupus. Constitutional symptoms — unexplained fevers, unintentional weight loss, profound fatigue beyond what the joint pain alone would explain — suggest systemic inflammatory disease rather than localized mechanical pathology. A well-designed rheumatology intake form turns these scattered symptoms into structured data that immediately informs the clinical assessment.

Laboratory and imaging history: what has already been measured

Most patients arriving at a rheumatology office have already had some workup performed by their primary care physician. The intake form needs to capture what has been tested, what the results were, and when the tests were performed, because repeating a comprehensive autoimmune panel that was drawn two weeks ago wastes resources, while acting on a negative ANA from five years ago when the patient had no symptoms is clinically meaningless.

The critical laboratory fields for a rheumatology intake include rheumatoid factor, anti-cyclic citrullinated peptide antibodies, antinuclear antibody titer and pattern, erythrocyte sedimentation rate, and C-reactive protein. RF and anti-CCP together are the serologic foundation of a rheumatoid arthritis diagnosis — anti-CCP in particular has high specificity, and a positive result in a patient with compatible symptoms is strongly suggestive even if the RF is negative. ANA is the gateway test for lupus and other connective tissue diseases, but a positive ANA alone is non-specific and occurs in up to fifteen percent of the healthy population, so the titer and pattern matter as much as the positive/negative result. ESR and CRP are inflammatory markers that help distinguish active inflammatory disease from quiescent or mechanical conditions, and trending them over time is more informative than a single value, which is why the form should capture the date alongside the result.

Imaging history is equally important. Prior X-rays of the hands and feet may already show the erosive changes characteristic of RA or the pencil-in-cup deformity of psoriatic arthritis. MRIs of affected joints may reveal synovitis, bone marrow edema, or tendon pathology that X-rays miss. The form should ask which imaging studies have been performed, which body regions were imaged, the approximate date, and whether the patient has copies or can request them from the ordering facility. This prevents the rheumatologist from ordering a study that was completed last month and sitting unread in another system.

Medication history: DMARDs, biologics, and the details that matter

The medication history section of a rheumatology intake is unlike any other specialty. Rheumatologic medications are powerful, require ongoing monitoring, and carry risk profiles that demand detailed documentation at every transition of care. A list of current medications with dosages is necessary but nowhere near sufficient. The form must capture prior disease-modifying antirheumatic drugs and biologics that have been tried, why they were stopped, and what monitoring was performed while the patient was on them.

Methotrexate is the anchor drug in rheumatoid arthritis treatment, and the intake needs to know whether the patient has taken it, at what dose, for how long, whether they experienced side effects such as nausea, liver enzyme elevation, mouth sores, or cytopenias, and whether they were compliant with folic acid supplementation and periodic CBC and hepatic function monitoring. Hydroxychloroquine is used across lupus, RA, and Sjogren syndrome, and carries a specific risk of retinal toxicity that requires annual ophthalmologic screening after five years of use — the form should capture whether screening has been performed and when. TNF inhibitors such as adalimumab, etanercept, and infliximab, along with newer biologics targeting IL-6, IL-17, JAK pathways, and B-cell depletion, each carry immunosuppression risks including reactivation of latent tuberculosis and hepatitis B. The form must ask about prior TB testing, hepatitis B and C serologies, and any serious infections experienced while on immunosuppressive therapy.

This is not information that can be captured with a generic "list your medications" field. A rheumatology intake form needs a structured medication table with columns for drug name, dose, start date, stop date, reason for discontinuation, and side effects experienced. Without this structure, the rheumatologist is forced to reconstruct the medication history verbally during the visit, which is time-consuming and error-prone — patients frequently forget dosages, confuse drug names, and underreport side effects unless prompted with specific questions.

Functional assessment: measuring what the disease does to daily life

Laboratory values and imaging findings describe the disease. Functional assessment describes what the disease does to the person living with it. A rheumatology intake should capture grip strength (can the patient open jars, turn keys, button shirts), walking capacity (distance before pain limits ambulation, need for assistive devices), ability to perform activities of daily living (bathing, dressing, cooking, climbing stairs), and work limitations (missed days, modified duties, disability status). These functional data points are essential for treatment decisions because the threshold for starting a biologic agent is different in a patient who is managing well with methotrexate and has mild morning stiffness versus a patient who can no longer dress independently or has lost their job due to hand dysfunction. Functional status also establishes a baseline for measuring treatment response — if the intake documents that the patient could walk only two blocks at presentation and three months later they are walking a mile, that is an outcome measure no lab value can replace.

Inflammatory versus degenerative: the distinction the form must make

This is the most important architectural decision in a rheumatology intake form, and it is the one most generic templates get wrong. Inflammatory arthritis and degenerative arthritis are not two points on the same spectrum — they are fundamentally different diseases with fundamentally different treatment pathways. Inflammatory disease requires immunosuppression. Degenerative disease requires pain management, physical therapy, and sometimes surgical intervention. Starting a patient with osteoarthritis on methotrexate is not just ineffective, it exposes them to the risks of immunosuppression with no possible benefit. Missing inflammatory disease in a patient with early RA delays the window for aggressive treatment that can prevent irreversible joint destruction.

The intake form enforces this distinction by structuring its questions to separate inflammatory signals from mechanical ones. Morning stiffness lasting more than thirty minutes, improvement with activity, symmetric small-joint involvement, elevated inflammatory markers, and positive autoimmune serologies all point toward inflammatory disease. Pain that worsens with use and improves with rest, asymmetric large-joint involvement, bony enlargement without warmth, normal inflammatory markers, and absence of autoimmune antibodies point toward degenerative disease. When these data points are scattered across an unstructured form, the pattern is hard to see. When they are organized into sections that explicitly sort inflammatory from mechanical features, the clinical picture emerges before the physician opens the exam room door. Practices building out their healthcare intake documentation should treat this inflammatory-versus-degenerative architecture as non-negotiable in any rheumatology form.

A rheumatology intake form that captures joint symptoms with diagnostic precision, screens for systemic autoimmune features the patient would not otherwise mention, documents laboratory and imaging history to avoid redundant testing, records a structured DMARD and biologic medication history with monitoring details, measures functional impact on daily life, and sorts inflammatory from degenerative signals at the form level is not a nice-to-have. It is the foundation of an efficient, thorough, and clinically sound first visit. Everything the rheumatologist does after that — the physical examination, the diagnostic workup, the treatment plan — builds on what the intake form captured. The form is where the medicine starts.

For related healthcare intake documentation across more than twenty specialties, browse the full catalog in our healthcare forms collection.

Rheumatology intake forms — $19.99 complete set

Fillable PDF intake form + client questionnaire. Joint symptom assessment, autoimmune screening, DMARD and biologic medication history, laboratory and imaging records, functional assessment, and inflammatory-versus-degenerative sorting. Built for rheumatology practices.

View Rheumatology Forms